Evidence map›Paper›PMID 38046032›Full record

ArticleClinical kidney journal2023

Adding 6-month parameters for the prediction of kidney prognosis in ANCA-associated glomerulonephritis.

Charlotte Boud'hors, Jérémie Riou, Nicolas Fage, Clément Samoreau, Alice Desouche, Philippe Gatault, Frank Bridoux, Cécile Martin, Samuel Wacrenier, Emeline Vinatier and 8 more

Abstract read
In one paragraph

Article in Clinical kidney journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Longitudinal Trajectories of Kidney Function in Patients with Severe ANCA-Associated Vasculitis.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Charlotte Boud'horsService de Néphrologie-Dialyse-Transplantation, CHU d'Angers, Angers, France.
Jérémie RiouDépartement de Méthodologie et Biostatistiques, Délégation pour la Recherche Clinique et l'Innovation, CHU d'Angers, Angers, France.
Nicolas FageService de Néphrologie-Dialyse-Transplantation, CHU d'Angers, Angers, France.
Clément SamoreauService de Néphrologie-Dialyse-Transplantation, CHU d'Angers, Angers, France.
Alice DesoucheService de Néphrologie-Dialyse-Transplantation, CHU d'Angers, Angers, France.
Philippe GataultService de Néphrologie-Dialyse-Transplantation, CHU de Tours, Tours, France.
Frank BridouxService de Néphrologie-Dialyse-Transplantation, CHU de Poitiers, Poitiers, France.
Cécile MartinService de Néphrologie-Dialyse-Transplantation, CHU de Poitiers, Poitiers, France.
Samuel WacrenierService de Néphrologie-Dialyse, Centre Hospitalier du Mans, Le Mans, France.
Emeline VinatierLaboratoire d'Immunologie et Allergologie, CHU Angers, Angers, France.
Assia DjemaService de Néphrologie-Dialyse, Centre Hospitalier de Cholet, Cholet, France.
Nicolas HenryService de Néphrologie-Dialyse, Centre Hospitalier de Laval, Laval, France.
Anne CrouéDépartement de pathologie cellulaire et tissulaire, CHU d'Angers, Angers, France.
Giorgina Barbara PiccoliLaboratoire d'Immunologie et Allergologie, CHU Angers, Angers, France.
Marie-Christine CopinUniversité d'Angers, Inserm, CNRS, Nantes Université, CRCI2NA, Angers, France.
Jean-François AugustoService de Néphrologie-Dialyse-Transplantation, CHU d'Angers, Angers, France.ORCID https://orcid.org/0000-0003-1498-2132
Benoît BrillandService de Néphrologie-Dialyse-Transplantation, CHU d'Angers, Angers, France.ORCID https://orcid.org/0000-0001-9622-4014
Maine-Anjou Registry Research Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Antineutrophil-cytoplasmic antibody (ANCA)-associated vasculitis (AAV) with kidney involvement (AAV-GN) frequently evolves to end-stage kidney disease (ESKD) despite aggressive immunosuppressive treatment. Several risk scores have been used to assess renal prognosis. We aimed to determine whether kidney function and markers of AAV-GN activity after 6 months could improve the prediction of ESKD. Methods: This retrospective and observational study included adult patients with AAV-GN recruited from six French nephrology centers (including from the Maine-Anjou AAV registry). The primary outcome was kidney survival. Analyses were conducted in the whole population and in a sub-population that did not develop ESKD early in the course of the disease. Results: When considering the 102 patients with all data available at diagnosis, Berden classification and Renal Risk Score (RRS) were not found to be better than kidney function [estimated glomerular filtration rate (eGFR)] alone at predicting ESKD (C-index = 0.70, 0.79, 0.82, respectively). Multivariables models did not indicate an improved prognostic value when compared with eGFR alone.When considering the 93 patients with all data available at 6 months, eGFR outperformed Berden classification and RRS (C-index = 0.88, 0.62, 0.69, respectively) to predict ESKD. RRS performed better when it was updated with the eGFR at 6 months instead of the baseline eGFR. While 6-month proteinuria was associated with ESKD and improved ESKD prediction, hematuria and serological remission did not. Conclusion: This work suggests the benefit of the reassessment of the kidney prognosis 6 months after AAV-GN diagnosis. Kidney function at this time remains the most reliable for predicting kidney outcome. Of the markers tested, persistent proteinuria at 6 months was the only one to slightly improve the prediction of ESKD.

Indexed as

ANCAESKDglomerulonephritisprognosisrenal function

Identifiers

PMID38046032
PMCPMC10689158

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.